<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523547</url>
  </required_header>
  <id_info>
    <org_study_id>HM-CAV-401</org_study_id>
    <nct_id>NCT02523547</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude</brief_title>
  <official_title>PhaseIVstudy to Evaluate the Non-inferiority of Cavir速Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude速 Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude速 Tab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority and safety in terms of HBV DNA
      undetectability comparing Baraclude Tab. in HBeAg(+) chronic hepatitis B patients treated
      with long-term Baraclude Tab.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with maintenance of HBV DNA undetectability</measure>
    <time_frame>48weeks</time_frame>
    <description>analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with HBeAg seroconversion</measure>
    <time_frame>at week 12, 24, 36 and 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with HBeAg seroclearance</measure>
    <time_frame>at week 12, 24, 36 and 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion with HBsAg seroclearance</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion with HBeAg seroconversion and HBsAb positive</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum HBV DNA levels</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HBsAg titer</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALanine amino Transferase (ALT)</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virologic breakthrough</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>virologic breakthrough is defined as the increase in serum HBV DNA (&gt;60IU/ml) as determined by at least 2 consecutive measurements of at least 3 month apart, during continued treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EuroQoL Five Dimensions Questionnaire-3L(EQ-5D-3L)</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Cavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir/0.5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir/0.5mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavir</intervention_name>
    <description>0.5mg/day</description>
    <arm_group_label>Cavir</arm_group_label>
    <other_name>entecavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude</intervention_name>
    <description>0.5mg/day</description>
    <arm_group_label>Baraclude</arm_group_label>
    <other_name>entecavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (over the19 years of age) currently taking Baraclude速 monotherapy for chronic
             HBV infection for at least 24 month with &lt; HBV DNA 60 IU/mL level, HBeAg positive and
             HBeAb negative status at screening.

        Exclusion Criteria:

          -  Patients are diagnosed Hepatitis cancer and hepatocellular carcinoma (HCC)

          -  Patient has concomitant other chronic viral infection (HAV/Hepatitis C Virus
             (HCV)/Hepatitis D Virus(HDV)/HIV)

          -  Patient had documented resistance mutations at any time before or at screening

          -  Patient has clinically confirmed alcoholism, autoimmune hepatitis, malignancy with
             hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency and Wilson's
             Disease.

          -  Patient has received antiviral agent including interferon other than Baraclude within
             24 months before screening for this study.

          -  Patient has received immunosuppressive agent within 24 weeks before screening or
             corticosteroids for 4 weeks.

          -  Clinical signs as indicated by any one of the following: Ccr(Cockroft-Gault) &lt;
             50ml/min, Total bilirubin &gt; 3.0 mg/dl, Albumin &lt; 2.7 g/dl, Prothrombin time &gt; INR 2.3

          -  Patient is pregnant or breastfeeding or willing to be pregnant

          -  Patient has malignancy except for thyroid cancer and Borderline malignancy.a history
             of treated malignancy is allowable if the patient's malignancy has been in complete
             remission, off chemotherapy and without additional surgical intervention, during the
             preceding five years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanmi Pharmaceutical</last_name>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EunSol Kim</last_name>
    <phone>+82-2-410-8747</phone>
    <email>snow-white@hanmi.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>15 Sites</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MoonHwa Park, MD</last_name>
      <phone>8224109190</phone>
      <email>moonwha.park@hanmi.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

